Neuropace, Inc. NPCE Research and development expenditures, capitalized for tax
Research and development expenditures, capitalized for tax at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept npce:DeferredTaxAssetsResearchAndDevelopmentExpendituresCapitalizedForTax.
The official record: Neuropace, Inc.’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neuropace, Inc.'s research and development expenditures, capitalized for tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neuropace, Inc.'s research and development expenditures, capitalized for tax?
- Neuropace, Inc. (NPCE) reported research and development expenditures, capitalized for tax of $12.07M in Q4 2025.
- How has Neuropace, Inc.'s research and development expenditures, capitalized for tax changed year-over-year?
- Neuropace, Inc.'s research and development expenditures, capitalized for tax decreased by 1.7% year-over-year, from $12.28M to $12.07M.
- What does research and development expenditures, capitalized for tax mean?
- This represents the tax-related deferred asset created by capitalizing research and development expenditures for tax reporting purposes rather than expensing them immediately. It reflects timing differences between financial accounting and tax accounting treatments of innovation costs. This asset indicates future tax deductions that will reduce the company's taxable income in subsequent periods.